Sunday, October 24, 2021

". . . we are facing the confusing situation in which people w/vaccine cards are no longer 'fully vaccinated'”.

"anyone who experiences adverse events or dies, and anyone who is diagnosed with COVID-19 before 2 weeks have passed after their second dose are not counted as deaths in the "fully vaccinated". That means that a person who is vaccinating might not be considered “Fully Vaccinated” until five weeks after their first dose." 

Further on, 

Close inspection of Moderna’s data made public ahead of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBAC) meeting that was scheduled for Dec. 17, 2020, however, reveals that among the vaccinated, an additional 81 participants and 118 among the placebo participants developed a COVID-19 diagnosis between the first and second shots. These participants were determined to be ineligible for the second dose and removed from the study. 

More damning.

CDC’s Director, Rochelle Walensky, said yesterday that CDC’s definition of “fully vaccinated” might need to be updated due to boosters. This semantic gameplay would back the population into mandated boosters if the OSHA rule through. Remember that it was Walensky who overruled the FDA’s decision to not recommend boosters for all. So now, we are facing the confusing situation in which people w/vaccine cards are no longer “fully vaccinated”. As we have seen, the efficacy of the current vaccines against extinct variants might be reasonably high (whatever it is), but the efficacy against extant variants seems to be in question. So, with eternal boosters, perhaps no one will ever be considered “Fully Vaccinated” in the US under CDC’s ever-changing definition. 

Semantic sleight of hand: 

We know that people who have had two doses are not considered “Fully Vaccinated” until day 14 after their second dose. So, when new cases occur in the partially vaccinated, they do not count toward cases in the vaccinated. There is significant evidence that COVID-19 vaccination may impair the immune system for a short period of time following administration; in particular, the likelihood of a SARS-CoV-2 infection, or infection by any other respiratory virus or bacterium may be more likely following vaccination. In animal trials on SARS and MERS viruses, close relatives of SARS-CoV-2, and in studies in humans of the RSV virus, this phenomenon was called “disease enhancement”. If disease enhancement is occurring after the first dose, or within two weeks following receipt of the second dose, the CDC’s semantics will bias the case count data and make it appear as if those exposed to vaccines have a lower risk of COVID-19 infection than those who are unvaccinated.

 

No comments:

Post a Comment